Leinco Technologies

Recombinant Human FGF-19

Product Code:
 
LEI-F150
Product Group:
 
Recombinant Proteins
Host Type:
 
Human
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-F150-25ug25 ug£489.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Long Description:
Fibroblast growth factor 19, also known as FGF19 is an atypical member of the fibroblast growth factor (FGF) family of proteins. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF19 uniquely binds to FGF receptor 4 (FGFR4).1 The FGF19 subfamily has reduced heparin binding resulting from a disrupted beta-trefoil domain. Reduced heparin binding allows these FGFs to diffuse beyond their site of origin and act as endocrine hormones. This family of FGFs is regulated, at least in part, by nuclear hormone receptors.2 Inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.3
NCBI Gene:
9965
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
FGF-19

References

1. French, DM. et al. (2008) Cancel Res. 68: 5086 2. Jones, S. et al. (2008) Mol Pharm. 5: 42 3. French, DM. et al. (2008) Oncogene 27: 85